Wed, June 1, 2011
Tue, May 31, 2011
Mon, May 30, 2011
Fri, May 27, 2011
Thu, May 26, 2011
Wed, May 25, 2011
Tue, May 24, 2011
Mon, May 23, 2011
Sun, May 22, 2011
Fri, May 20, 2011
Thu, May 19, 2011
Wed, May 18, 2011
Tue, May 17, 2011
Mon, May 16, 2011
Sun, May 15, 2011
[ Sun, May 15th 2011 ] - Market Wire
Teva to Acquire Taiyo
Fri, May 13, 2011
Thu, May 12, 2011
Wed, May 11, 2011
Tue, May 10, 2011
Mon, May 9, 2011
Sun, May 8, 2011
Sat, May 7, 2011
Fri, May 6, 2011
Thu, May 5, 2011
Wed, May 4, 2011

Curis to Present at the 2nd Annual ThinkEquity Healthcare Conference


//health-fitness.news-articles.net/content/2011/ .. nd-annual-thinkequity-healthcare-conference.html
Published in Health and Fitness on Wednesday, May 18th 2011 at 6:06 GMT by Market Wire   Print publication without navigation


LEXINGTON, Mass.--([ BUSINESS WIRE ])--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the 2nd Annual ThinkEquity Healthcare Conference at 12:30 p.m. EDT on May 25, 2011, in New York City.

Dan Passeri, President and Chief Executive Officer, will provide an overview of Curisa™ proprietary drug candidates including CUDC-101, a first-in-class HDAC/EGFR/Her2 inhibitor, and CUDC-907, an HDAC/PI3 kinase inhibitor. Mr. Passeri will also discuss the status of Curisa™ partnered programs including lead molecule vismodegib (GDC-0449, RG3616), an orally-administered small molecule Hedgehog Pathway Inhibitor that is being developed by Curisa™ collaborator Genentech, and Debio 0932, an HSP90 inhibitor that is under development by Curisa™ licensee Debiopharm. Mr. Passeri will also discuss other corporate activities.

There will be a corresponding webcast of the presentation, which can be accessed by visiting:

[ http://wsw.com/webcast/tep20/cris/ ]

The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at [ www.curis.com ].

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at [ www.curis.com ].


Publication Contributing Sources